CA2375378A1 - Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines - Google Patents
Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines Download PDFInfo
- Publication number
- CA2375378A1 CA2375378A1 CA002375378A CA2375378A CA2375378A1 CA 2375378 A1 CA2375378 A1 CA 2375378A1 CA 002375378 A CA002375378 A CA 002375378A CA 2375378 A CA2375378 A CA 2375378A CA 2375378 A1 CA2375378 A1 CA 2375378A1
- Authority
- CA
- Canada
- Prior art keywords
- antilipemic
- carnitines
- hmg
- combinations
- coa reductase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 230000002402 anti-lipaemic effect Effects 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 239000003524 antilipemic agent Substances 0.000 abstract 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 abstract 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- -1 alkanoyl L-carnitine Chemical compound 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960003765 fluvastatin Drugs 0.000 abstract 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
- 229960004844 lovastatin Drugs 0.000 abstract 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13800899P | 1999-06-08 | 1999-06-08 | |
| US60/138,008 | 1999-06-08 | ||
| EP99830415.8 | 1999-06-30 | ||
| EP99830415A EP1064943B1 (fr) | 1999-06-30 | 1999-06-30 | Combinaison ayant une activité hypolipémiante substantiellement dénuée des effets toxiques ou effets secondaires causés par les médicaments à activité hypolipémiante |
| PCT/EP2000/005091 WO2000074675A1 (fr) | 1999-06-08 | 2000-06-05 | Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2375378A1 true CA2375378A1 (fr) | 2000-12-14 |
| CA2375378C CA2375378C (fr) | 2009-08-11 |
Family
ID=26153794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002375378A Expired - Fee Related CA2375378C (fr) | 1999-06-08 | 2000-06-05 | Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP2003501385A (fr) |
| KR (1) | KR100725263B1 (fr) |
| AU (1) | AU782188B2 (fr) |
| CA (1) | CA2375378C (fr) |
| CZ (1) | CZ20014218A3 (fr) |
| HU (1) | HUP0201597A3 (fr) |
| MX (1) | MXPA01012644A (fr) |
| PL (1) | PL197899B1 (fr) |
| SK (1) | SK285900B6 (fr) |
| WO (1) | WO2000074675A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2678746C (fr) * | 2007-02-27 | 2018-05-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition a utiliser pour le traitement du diabete de type 2 |
| SG10201507488RA (en) * | 2007-03-21 | 2015-10-29 | Sigma Tau Ind Farmaceuti | Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance |
| US20110052556A1 (en) | 2008-02-29 | 2011-03-03 | Biolab Sanus Farmaceutical Ltda | Pharmaceutical composition comprising racetam and carnitine and process for its preparation |
| US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0667833B2 (ja) * | 1985-11-28 | 1994-08-31 | 雪印乳業株式会社 | 経腸栄養剤 |
| CA2007983C (fr) * | 1989-01-18 | 1996-12-10 | Michael S. Brown | Coenzyme q10 avec inhibiteurs de la hmg-coa |
| IT1293067B1 (it) * | 1997-07-01 | 1999-02-11 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico |
-
2000
- 2000-06-05 CZ CZ20014218A patent/CZ20014218A3/cs unknown
- 2000-06-05 WO PCT/EP2000/005091 patent/WO2000074675A1/fr not_active Application Discontinuation
- 2000-06-05 PL PL352106A patent/PL197899B1/pl unknown
- 2000-06-05 KR KR1020017015675A patent/KR100725263B1/ko not_active IP Right Cessation
- 2000-06-05 AU AU59697/00A patent/AU782188B2/en not_active Ceased
- 2000-06-05 CA CA002375378A patent/CA2375378C/fr not_active Expired - Fee Related
- 2000-06-05 HU HU0201597A patent/HUP0201597A3/hu unknown
- 2000-06-05 JP JP2001501212A patent/JP2003501385A/ja active Pending
- 2000-06-05 SK SK1715-2001A patent/SK285900B6/sk not_active IP Right Cessation
- 2000-06-05 MX MXPA01012644A patent/MXPA01012644A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020025066A (ko) | 2002-04-03 |
| HUP0201597A3 (en) | 2003-04-28 |
| HUP0201597A2 (en) | 2002-09-28 |
| AU782188B2 (en) | 2005-07-07 |
| JP2003501385A (ja) | 2003-01-14 |
| PL197899B1 (pl) | 2008-05-30 |
| SK17152001A3 (sk) | 2002-03-05 |
| CA2375378C (fr) | 2009-08-11 |
| SK285900B6 (sk) | 2007-10-04 |
| MXPA01012644A (es) | 2002-07-22 |
| PL352106A1 (en) | 2003-07-28 |
| KR100725263B1 (ko) | 2007-06-07 |
| CZ20014218A3 (cs) | 2002-04-17 |
| AU5969700A (en) | 2000-12-28 |
| WO2000074675A1 (fr) | 2000-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105559A (en) | STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR | |
| CA2324283A1 (fr) | Composition pharmaceutique contenant une statine et de l'aspirine | |
| IE970731A1 (en) | Product and method for the treatment of hyperlipidemia | |
| WO2000048626A3 (fr) | Compositions aerosol d'inhibiteurs de hmg-coa reductase permettant d'inhiber l'inflammation associee a une maladie pulmonaire | |
| AU2000264559A1 (en) | Pharmaceutical compositions comprising a hmg coa reductase inhibitor | |
| CA2268438A1 (fr) | Hesperidine et hesperetine utilisees en tant qu'inhibiteur de 3-hydroxy-3-methyl-glutaryl coenzyme a (hmg coa) reductase | |
| EP1314425A4 (fr) | Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque | |
| GR3032929T3 (en) | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound. | |
| GEP20053548B (en) | Sugar-Substituted 2-Azetidinones Useful as Hypocholesterolemic Agents | |
| WO2002089788A3 (fr) | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase | |
| EE03853B1 (et) | Antitrombootiline ja antiaterogeenne farmatseutiline kompositsioon, mis sisaldab tienopüridiini derivaati ja HMG-CoA-reduktaasi inhibiitorit | |
| MY118381A (en) | Statin-carboxyalkylether combinations | |
| AU3035600A (en) | Combination of cerivastatin and fibrates | |
| CA2375378A1 (fr) | Combinaisons antilipemiques comprenant des inhibiteurs de hmg-coa reductase et des carnitines | |
| AU1166101A (en) | Pharmaceutical combination comprising separate dosage forms in a compliance package of an inhibitor of hmg coa reductase and fibric acid derivative | |
| EP1604658A3 (fr) | Composition pharmaceutique contenant de l'ibuprofen et de la prochlorperazine | |
| AU2002353659A1 (en) | Simvastatin dosage forms | |
| NO20063867L (no) | Hypokolesterolemisk sammensetning omfattende et staten og et antiflatulensmiddel | |
| DE69923670D1 (de) | Lipidsenkende Kombination, die im wesentlichen frei ist von toxischen Wirkungen und Nebenwirkungen der Lipidsenker | |
| WO2005058310A3 (fr) | Utilisation de composes organiques | |
| BG106918A (en) | Perocess for the preparation of sodium salts of statins | |
| AU2116201A (en) | A therapeutic mixture of hmg-coa reductase inhibitors | |
| AU4578197A (en) | Pharmaceutical compositions comprising hmg-coa reductase inhibitors, in particular fluvastatin | |
| AU2001289428A1 (en) | Oral pharmaceutical composition containing a combination of fenofibrate and a hmg-coa reductase inhibitor | |
| CO5611117A2 (es) | Combinacion de compuestos organicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170605 |